Background: As age-related infirmity often influences treatment options and outcome of esophageal cancer, the optimization of treatment for the elderly, especially in octogenarians, has been the subject of considerable debate. Methods: We performed a retrospective, multi-institutional survey to assess the effectof age on the outcome of definitive radiotherapy for esophageal cancer by a questionnaire sent to eight institutions in Japan. Results: Therewere362evaluable replies. Thepatients included 317 males and 45 females, with a median age of 72 years (range 35-93 years), and 96% had squamous cell carcinoma. There were30 clinical stage I, 71 stage IIA,17 stage IIB, 113 stage III and 116 stage IV cases. The stage was not specified in 16 cases. Multiple co-morbidities existed in 40°!c> of the patients who were 70 years of age or older. Therewas no statistically significant age-related difference in the incidence of adverse reactions to radiotherapy (P > 0.05). Overall survival was more significantly affected by Karnofsky Performance Statusthan by the patient's age. The influence of performance status on cumulative survival for stage I and II disease was more pronounced in patients in their 80s. Conclusion: The safety of radiotherapy for esophageal carcinoma is not influenced by the patient's age. Because the performance status strongly influenced survival, the multi-disciplinary assessment of functional status is mandatory for optimizing the choice of treatmentfor patients in their 80s with esophageal cancer.
INTRODUCTION
An estimated 9600 new cases of esophageal cancer occur annually in Japan. The age-specific incidence increases precipitouslywith age and in men reaches a peak of approximately 85.0 cancer incidence per 100 000 in the age range 75-84 years (1) . As age-related infirmity often influences treatment options and outcome, the diagnosis, general performance status, method of DRT, use of systemic chemotherapy (CTx), response, presence of various co-morbid conditions, adverse reactions and survival. Concerning staging of the disease, estimation of the depth of invasion and nodal status were based on esophagographic, endoscopic and computed tomographic findings.
General performance status was assessed according to the Kamofsky Performance Status (KPS) scale (6) . Concerning the method of DRT, the use of intracavitary irradiation (JCRT) and alteredfractionation (ALF) was assessed,and also the total dose. The components of the CTx were not investigatedin detail, but platinum and fluorouracil derivatives were used most frequently.
To evaluate the response, we used the following criteria: complete response (CR), disappearance of the tumor on esophagography, computed tomography and endoscopic examinations; partial response (PR), shrinkage in size by 50% or more in length times width of the tumor; no change (NC), a <50% decrease or a <25% increase in size; and progressive disease (PD), a~5% increase in size. Responses were evaluated 4 weeks after the end of the DRT.
The total dose administered to the tumor was expressed as the sum of the dose of each reference point when ICRT had been combined with external beam.
Co-morbid conditions, such as smoking, cerebrovascular disease, dementia, other neurological deficits (Parkinsonism, etc.), ischemic heart disease, hypertension, arrhythmia, diabetes, chronic lung, liver or renal disease, anemia (hemoglobin content ::;12g/dl) and a history of other malignancies were assessed as to whether they required treatment.
Estimation of adverse reaction was based on the RTOG/ EORTC Late Radiation Morbidity Scoring Scheme (7).
COMPARISON AMONG AGE GROUPS
The following variables were compared among age groups: (a) distribution of clinical stage, KPS and the number of co-morbid conditions; (b) completion of the administration of ;;::60 Gy of radiation; (c) adverse reactions; and (d) overall survival.
ESTIMATION OF FACTORS
Multivariate analyses were carried out to estimate the influence of the following factors on overall survival: clinical stage (Jill vs ill/IV), KPS (;;::80 or ::;70), age (;;::80 or <80), dose (;;::60 Gy or <60 Gy), use of ICRT or CTx, response (CR vs non-CR) and co-morbid conditions.
STATISTICS
Overall survival rates were estimated using the Kaplan-Meier method. Differences in survival were compared with the generalized Wilcoxon test and multivariate analysis was performed with Cox's proportional hazards method. Other methods used are described at the appropriate location.
RESULTS

REPLIES
Three hundred and sixty-five replies were received. Three of them with no description of survival were excluded. Of these 362 remaining cases, there were 317 males and 45 females with a median age of 72 years (range 35-93 years). A histological diagnosis was obtained in 344 cases, with 330 (95.9%) being described as squamous cell carcinoma. Of the others, there were six (1.7%) undifferentiated carcinomas, three (0.8%) adenocarcinomas, three carcinosarcomas, one (0.02%) sarcoma (not otherwise specified) and one adenosquamous carcinoma. Two patients were 93 years of age and they were included with the octogenarians in the analysis.
COMPARISON AMONG AGE GROUPS
CLINICAL STAGE, KPS, CO-MORBID CONDITIONS
The proportion of patients with earlier clinical stage and poor functional status increased with age (Table 1 ).
There was a higher incidence of chronic cardiovascular and pulmonary diseases in the older age groups and a large proportion of patients smoked in each age group. More than 70% of the patients in their 60s or older had at least one co-morbid condition and approximately 40% in their 70s or older had multiple co-morbid conditions.
COMPLETION OF THE ADMINISTRATION OF ;;::60 GY
A cumulative dose of ;;::60 Gy was administered to 278 patients and the response rates according to the stages are summarized in Table 2 . The rate ofcompleteness of the administration of ;;::60 Gy was higher in octogenarians than in younger patients.
The fractionation schedule was described in 351 replies. Three hundred and thirty-six patients were treated with once a day with 3-5 fractions per week. The dose administered in each fraction ranged from 1.4 to 3.0 Gy (median 2.0 Gy). ALF was used in 15 cases. As the number was small, the differences derived from ALP were ignored in the following analyses.
Ninety-eight patients underwent ICRT. This option was based on clinical stage (P =0.0001) and the institution (P =0.0002) and not on the age (P =0.544) or KPS (P = 0.838), according to multiple regression analysis. CTx was used predominantly for patients with advanced-stage disease. The proportion of patients receiving CTx became smaller as the age increased. Planned split course irradiation with a 2-or 3-week rest was used in 22 cases. Excluding these, delay in treatment of more than 2 weeks occurred in 60 cases, but the incidence of treatment delay did not correlate significantly with age (P = 0.610; chi-squared test). As the survival rate was not influenced by treatment delay of more than 2 weeks (P = 0.877 for stages I and IT and P = 0.973 for stages ill and IV), we did not take treatment delays into account in the following analyses. The main reason for a reduction in dose to <60 Gy was progression of the disease in the younger patients and refusal of treatment in the elderly. 
ADVERSE REACTIONS
For patients who survived at least 3 months post-irradiation (n = 323), the incidence of an adverse reaction was 8.4% (Table  NO TAG ).The incidence of adversereaction of each gradewas not statistically significant among each age group (P = 0.386; KruskalWallis test). Octogenarians had a slightlyhigherincidence of adverse reactions although the difference was not statistically significant comparedwith the youngerage groups (P= 0.137; Mann-Whitney U test).Nine cases (2.8% of the 323 cases)experienced toxicities of grade 3 or higher ( Table 4 ). The incidence of grade 3 or higher toxicity was not related to whether the patient was octogenarian or not (P = 0.405; Mann-Whitney U test). months 
OVERALL SURVIVAL
The mediansurvival of all the 362 cases was 8.8 monthsand the 3-and 5-yearsurvivalrates were 13.5 and 6.8%, respectively (Fig. 1) . According to Cox's proportional hazards analysis, the clinical stage, KPS, response and dose significantly affected overall survival, whereas the other factors, i.e. the use of CTx or ICRT, the presence or absence of co-morbid conditions and the patient's age, did not (Table 5) .
ESTIMATION OF FACTORS
For patients with early stage disease (I, IIA and lIB), the overall survival rate of the octogenarians was significantly affected by the KPS (P = 0.009), while the KPS did not affect the survival of younger patients (P = 0.958). In contrast, for the advanced stages (ill and IV), the overall survival of the patients younger than 80 years was affected significantly by the KPS (P =0.048), whereas it was not in the octogenarians (P =0.963). This difference in survival in the advanced stages due to KPS was attributed to a decrease in long-term survivors (Fig. 2a-d) . Ch., combination of chemotherapy; EBR, external beam irradiation; ICR, intracavitary irradiation; UK, unknown; NOS, not obviously specified; Sm, habit of smoking: IHD, ischemic heart disease; HT, hypertension; DM, diabetes mellitus; CLD, chronic liver disease; DOD, died of esophageal cancer; TRD, treatment-related death; DID, died of intercurrent disease; MI, myocardial infarction; RP, radiation peumonitis; RM, radiation myelopathy; pneum., pneumonia; CPD, chronic lung disease; TEF, tracheoesophageal fistula; CP, constrictive pericarditis. Other factors (Tx. methods, co-morbid conditions, etc.); P > 0.15. *Total dose estimated at each reference point, regarding cases which had been combined with brachytherapy; TX., treatment; CR, complete response.
DISCUSSION
In this study, we examined the clinical features of esophageal cancer in octogenarians treated by DRT. The proportion of patients with early-stage disease increased with age. This probably reflects the fact that younger patients with early-stage cancer were treated mainly with surgery, rather than the real distribution of clinical stage according to age. As would be expected, clinical stage, tumor response and administered dose significantly correlated with overall survival according to Cox's proportional hazards analysis. More octogenarians received 260 Gy of radiation than did the younger patients. This may be due to the fact that, in the younger age group, a large number of patients had advanced cancer and subsequently had a poorer overall condition in general making many of them candidates only for palliative treatment.
The physicians we surveyed hesitated to use chemotherapy for octogenarians. Nevertheless, the incidence of subacute and/or late adverse reactions was higher in octogenarians (12.7%) than in younger patients (P = 0.137). This suggests that careful attention to the safety of DRT is mandatory in this age group. However, the incidence of severe adverse reactions (zgrade 3) was not different in octogenarians (P = 0.405). Therefore, DRT is safe in the octogenarians, with careful attention to the patient's condition.
Chronic cardiovascular and pulmonary disease, which are thought to influence the safety of DRT for esophageal cancer, occurred frequently in patients 60 years and older. Moreover, since more than 40% of the patients in their 70s or older presented with multiple co-morbid conditions, their influence on the safety and outcome of DRT in this age group must be carefully considered. Needless to say, selection biases that obscure the influence of age-related infirmity should be kept in mind. Candidates for DRT must be able to tolerate the accompanying toxicity. The co-morbid conditions we surveyed had no significant influence on survival. However, their severity was not investigated in detail and this may be reflected in the results. It should be emphasized that KPS strongly influenced the outcome, especially in the octogenarians with stage IIII disease (Fig. 2) . For these early-stage patients, the survival was the same as that of younger patients if the KPS was :::80, but if the KPS was s70, their survival was equivalent to that of patients with more advanced disease. The multidisciplinary evaluation of a functional status alternative to KPS is thought to be required to elucidate the causal relationship between age-related infirmity and survival, if any, and to distinguish it from the influence of cancer-related factors. This will optimize treatment, not only for cure, but also for shortand medium-term quality of life (8) (9) (10) .
Malnutrition frequently causes deterioration of the functional status of patients with advanced-stage disease (11 this condition (12) (13) (14) and it is important to clarify whether this is reflected in the outcome. The results of this study suggest that the safety of DRT is not influenced by the patient's age. Okawa et al. (15) have indicated that the effectiveness of DRT for superficial esophageal cancer is promising and that it could be an alternative to surgery. It has been shown that the safety of radical esophagectomy diminishes precipitously with age (4, 16, 17) . As DRThas the great advantage of preserving organ function, an attempt should be made to compare the survival and functional outcome between DRT and surgery for esophageal cancer, especially in octogenarians.
